Kapadia Sandip 4

What Happened
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences (HRMY), sold 3,746 shares of company common stock in an open-market transaction on January 26, 2026. The weighted average sale price was $37.15 per share, for total proceeds of approximately $139,171. This disposition was reported on a Form 4 filed January 28, 2026.

Key Details

• Transaction date: January 26, 2026; Form 4 filed January 28, 2026 (appears timely under the standard 2-business-day rule).
• Quantity and price: 3,746 shares sold; weighted average price $37.15; individual trade prices ranged from $36.57 to $37.70.
• Total value: Approximately $139,171.
• Plan/footnotes: Sale was made pursuant to a pre-established Rule 10b5‑1 trading plan (Footnote 1). Price shown is a weighted average; the filer can provide per-trade breakdown on request (Footnote 2).
• Correction: The filing notes a correction to a prior Form 4 (filed Jan 26, 2026) that had misstated the number of shares beneficially owned; the current filing corrects that figure (Footnote 3).
• Shares owned after transaction: Reported in the Form 4 (corrected), but the specific post-sale holding is not provided in this summary.

Context

• Sales executed under a Rule 10b5‑1 plan are pre-scheduled and are commonly used by insiders to crystallize gains or meet liquidity needs; such sales do not necessarily signal a change in the insider’s view of the company.
• For retail investors tracking insider activity, purchases generally carry more informational weight than routine, pre-planned sales. This filing documents a routine sale by the CFO rather than an acquisition or exercise.